1. Home
  2. BDSX vs ATOS Comparison

BDSX vs ATOS Comparison

Compare BDSX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • ATOS
  • Stock Information
  • Founded
  • BDSX 2005
  • ATOS 2009
  • Country
  • BDSX United States
  • ATOS United States
  • Employees
  • BDSX N/A
  • ATOS N/A
  • Industry
  • BDSX Precision Instruments
  • ATOS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BDSX Health Care
  • ATOS Health Care
  • Exchange
  • BDSX Nasdaq
  • ATOS Nasdaq
  • Market Cap
  • BDSX 115.4M
  • ATOS 112.5M
  • IPO Year
  • BDSX 2020
  • ATOS 2012
  • Fundamental
  • Price
  • BDSX $0.26
  • ATOS $0.79
  • Analyst Decision
  • BDSX Strong Buy
  • ATOS Strong Buy
  • Analyst Count
  • BDSX 5
  • ATOS 3
  • Target Price
  • BDSX $1.75
  • ATOS $6.17
  • AVG Volume (30 Days)
  • BDSX 2.9M
  • ATOS 656.4K
  • Earning Date
  • BDSX 08-06-2025
  • ATOS 08-11-2025
  • Dividend Yield
  • BDSX N/A
  • ATOS N/A
  • EPS Growth
  • BDSX N/A
  • ATOS N/A
  • EPS
  • BDSX N/A
  • ATOS N/A
  • Revenue
  • BDSX $74,463,000.00
  • ATOS N/A
  • Revenue This Year
  • BDSX $17.29
  • ATOS N/A
  • Revenue Next Year
  • BDSX $29.33
  • ATOS N/A
  • P/E Ratio
  • BDSX N/A
  • ATOS N/A
  • Revenue Growth
  • BDSX 35.76
  • ATOS N/A
  • 52 Week Low
  • BDSX $0.17
  • ATOS $0.55
  • 52 Week High
  • BDSX $2.04
  • ATOS $1.66
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 38.93
  • ATOS 44.68
  • Support Level
  • BDSX $0.27
  • ATOS $0.80
  • Resistance Level
  • BDSX $0.33
  • ATOS $0.86
  • Average True Range (ATR)
  • BDSX 0.03
  • ATOS 0.05
  • MACD
  • BDSX 0.01
  • ATOS -0.01
  • Stochastic Oscillator
  • BDSX 19.54
  • ATOS 17.33

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: